The American Cancer Society and Melanoma Research Alliance have selected two new promising projects in a second round of funding under a partnership between the two organizations. The first grants funded through the partnership, in 2018, focused on advancing research to reduce side effects resulting from cancer treatments with immune-checkpoint inhibitors. This year’s grants will support two interdisciplinary teams to better understand and manage metastasis of melanoma and other types of cancer.
The new grants, each funded at $1 million total, will go to teams led by Michael A. Davies, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and Eva Hernando, PhD, of New York University School of Medicine.
Dr. Davies’ team will explore whether molecular and immune features of individual melanomas can predict which patients will develop central nervous system metastases. They will also test an experimental new treatment for brain metastases, IACS-010759, which is currently in clinical trials. The team will determine whether the drug can improve survival in combination with U.S. Food and Drug Administration–approved targeted therapies. The team will also test the drug in patients with other cancers (ie, lung cancer, breast cancer), to see if it can improve treatments used for brain metastases from those diseases.
Dr. Hernando and her team will investigate the role of amyloid beta in brain metastasis. Dr. Hernando’s lab has analyzed the protein content of melanoma that had spread to the brain, and found, surprisingly, elevated rates of amyloid processing protein (AAP), the same protein that plays a central role in the development of Alzheimer’s disease. The team will investigate how APP, which generates amyloid beta, influences melanoma growth within the brain microenvironment; determine the therapeutic potential of targeting APP using antibodies and compounds that have already being tested clinically in Alzheimer’s patients; and assess whether APP is required for brain metastasis of other tumors, such as lung and breast cancers.
The grants are funded under a joint agreement between Melanoma Research Alliance and the American Cancer Society that began in 2018. Each organization will contribute $1 million to support the two teams over 3 years. By combining funding and networks, the groups can help deliver breakthroughs faster. The new multiyear grants go into effect January 1, 2020.
For more information about the partnership, please visit www.cancer.org/MRA. ■